Apellis Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03753U1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of Lukas Scheibler. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Lukas Scheibler has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:APLS / Apellis Pharmaceuticals, Inc. Chief Research Officer 68,299
US:M?????? / KUBOTA PHARMACEUTICAL HOLDINGS CO LTD EVP of Research & Development 66,587
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Lukas Scheibler. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases APLS / Apellis Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APLS / Apellis Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-05-24 APLS SCHEIBLER LUKAS 2,935 20.3700 2,935 20.3700 59,786 26 24.21 11,271 18.85

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insider Sales APLS / Apellis Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in APLS / Apellis Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2023-09-06 APLS SCHEIBLER LUKAS 1,756 43.0100 1,756 43.0100 75,526 336 33.5900 -16,541 -21.90
2021-06-10 APLS SCHEIBLER LUKAS 3,417 60.0000 3,417 60.0000 205,020

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Lukas Scheibler as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-12-05 2023-12-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -10,000 68,299 -12.77 60.00 -600,000 4,097,940
2023-12-05 2023-12-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 10,000 78,299 14.64 13.85 138,500 1,084,441
2023-09-07 2023-09-06 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -1,756 68,299 -2.51 43.01 -75,526 2,937,540
2023-02-22 2023-02-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -715 69,643 -1.02 58.50 -41,828 4,074,116
2023-02-22 2023-02-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 9,886 70,358 16.35
2023-02-14 2023-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -678 60,472 -1.11 51.21 -34,720 3,096,771
2023-01-30 2023-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -542 61,150 -0.88 52.77 -28,601 3,226,886
2023-01-24 2023-01-20 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -2,015 61,692 -3.16 52.05 -104,881 3,211,069
2023-01-17 2023-01-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 22,580 63,707 54.90
2022-05-31 2022-05-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -10,000 40,358 -19.86 43.00 -430,000 1,735,394
2022-05-31 2022-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
J - Other -11,250 0 -100.00
2022-05-31 2022-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other -1,875 50,358 -3.59
2022-04-06 2022-04-05 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -609 49,391 -1.22
2022-04-06 2022-04-05 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -609 52,233 -1.15 60.09 -36,593 3,138,524
2022-04-06 2022-04-05 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 609 52,842 1.17 13.85 8,435 731,862
2022-04-05 2022-04-04 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -3,504 50,000 -6.55
2022-04-05 2022-04-04 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1,249 52,233 -2.34 57.80 -72,198 3,019,329
2022-04-05 2022-04-04 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1,437 53,482 -2.62 56.86 -81,714 3,041,200
2022-04-05 2022-04-04 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -818 54,919 -1.47 55.84 -45,677 3,066,677
2022-04-05 2022-04-04 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 3,504 55,737 6.71 13.85 48,530 771,957
2022-04-04 2022-04-01 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -11,496 53,504 -17.69
2022-04-04 2022-04-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -11,496 52,233 -18.04 55.05 -632,855 2,875,427
2022-04-04 2022-04-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 11,496 63,729 22.01 13.85 159,220 882,647
2022-02-15 2022-02-14 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -720 133,777 -0.54
2022-02-15 2022-02-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 720 52,233 1.40 26.73 19,246 1,396,188
2022-02-14 2022-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -10,000 65,000 -13.33
2022-02-14 2022-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -10,000 53,179 -15.83 50.00 -500,000 2,658,950
2022-02-14 2022-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 10,000 63,179 18.80 13.85 138,500 875,029
2022-02-14 2022-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -678 53,179 -1.26 47.12 -31,947 2,505,794
2022-02-14 2022-02-11 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1,666 51,513 -3.13 46.80 -77,969 2,410,808
2022-02-10 2022-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -10,000 75,000 -11.76
2022-02-10 2022-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -10,000 53,857 -15.66 45.00 -450,000 2,423,565
2022-02-10 2022-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 10,000 63,857 18.57 13.85 138,500 884,419
2022-02-01 2022-01-31 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1,233 53,857 -2.24 38.47 -47,434 2,071,879
2022-02-01 2022-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -642 55,090 -1.15 38.59 -24,775 2,125,923
2022-01-25 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 36,951 36,951
2022-01-25 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 26,051 55,732 87.77
2022-01-24 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -3,021 134,497 -2.20
2022-01-24 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 3,021 29,681 11.33 26.73 80,751 793,373
2021-06-11 2021-06-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -3,417 26,651 -11.36 60.00 -205,020 1,599,060
2021-02-11 2021-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -680 29,290 -2.27 47.72 -32,450 1,397,719
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 11,250 11,250
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 45,000 45,000
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 1,875 29,970 6.67
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 7,500 28,095 36.42
2020-12-09 2020-12-08 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -7,482 137,518 -5.16
2020-12-09 2020-12-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 7,482 20,595 57.06 26.73 199,994 550,504
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy)
A - Award 56,250 56,250
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 9,375 12,310 319.42
2019-02-12 2019-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy)
A - Award 85,000 85,000
2018-05-29 2018-05-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
P - Purchase 2,935 2,935 20.37 59,786 59,786
2018-04-17 2018-04-13 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 145,000 145,000
2018-04-17 3 APLS Apellis Pharmaceuticals, Inc.
No securities are beneficially owned
0
2017-07-18 2017-07-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Share Acquisition Right (right to buy)
M - Exercise -2,663 66,587 -3.85
2017-07-18 2017-07-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
S - Sale -1,250 11,108 -10.11 6.50 -8,125 72,202
2017-07-18 2017-07-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
M - Exercise 2,663 12,358 27.47
2017-06-20 2017-06-20 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
S - Sale -1,300 9,695 -11.82 6.95 -9,035 67,380
2017-06-20 2017-06-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Share Acquisition Right (right to buy)
M - Exercise -2,664 69,250 -3.70
2017-06-20 2017-06-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
M - Exercise 2,664 10,995 31.98
2017-05-18 2017-05-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Share Acquisition Right (right to buy)
M - Exercise -2,663 71,914 -3.57
2017-05-18 2017-05-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
S - Sale -1,275 8,331 -13.27 6.15 -7,841 51,236
2017-05-18 2017-05-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
M - Exercise 2,663 9,606 38.36
2017-04-17 2017-04-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Share Acquisition Right (right to buy)
M - Exercise -2,664 74,577 -3.45
2017-04-17 2017-04-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
S - Sale -1,320 6,943 -15.97 6.48 -8,554 44,991
2017-04-17 2017-04-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
M - Exercise 2,664 8,263 47.58
2017-03-20 2017-03-20 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
S - Sale -1,250 5,599 -18.25 7.10 -8,875 39,753
2017-03-20 2017-03-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Share Acquisition Right (right to buy)
M - Exercise 2,663 77,241 3.57
2017-03-20 2017-03-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
M - Exercise 2,663 6,849 63.62
2017-02-21 2017-02-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Share Acquisition Right (right to buy)
M - Exercise 2,664 79,904 3.45
2017-02-21 2017-02-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
S - Sale -1,450 4,186 -25.73 8.10 -11,745 33,907
2017-02-21 2017-02-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
M - Exercise 2,664 5,636 89.64
2017-01-20 2017-01-18 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
S - Sale -1,475 2,972 -33.17 8.70 -12,832 25,856
2017-01-20 2017-01-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Share Acquisition Right (right to buy)
M - Exercise -2,663 82,568 -3.12
2017-01-20 2017-01-17 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
M - Exercise 2,663 4,447 149.27
2016-12-27 2016-12-22 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Stock Option (right to buy)
M - Exercise 2,664 85,231 3.23
2016-12-27 2016-12-22 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
S - Sale -880 1,784 -33.03 8.18 -7,198 14,593
2016-12-27 2016-12-22 4 M?????? KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Common Stock
M - Exercise 2,664 2,664
2016-11-21 2016-11-21 4 M?????? ACUCELA INC.
Common Stock
S - Sale -2,663 0 -100.00 9.35 -24,891
2016-11-21 2016-11-17 4 M?????? ACUCELA INC.
Restricted Stock Unit
M - Exercise -2,663 87,895 -2.94
2016-11-21 2016-11-17 4 M?????? ACUCELA INC.
Common Stock
M - Exercise 2,663 2,663
2016-11-15 2016-11-14 4 M?????? ACUCELA INC.
Common Stock
S - Sale -1,774 0 -100.00 9.44 -16,745
2016-10-18 2016-10-17 4 M?????? ACUCELA INC.
Restricted Stock Unit
M - Exercise -2,664 90,558 -2.86
2016-10-18 2016-10-17 4 M?????? ACUCELA INC.
Common Stock
F - Taxes -890 1,774 -33.41 11.48 -10,220 20,372
2016-10-18 2016-10-17 4 M?????? ACUCELA INC.
Common Stock
M - Exercise 2,664 2,664
2016-09-20 2016-09-20 4 M?????? ACUCELA INC.
Common Stock
S - Sale -2,663 0 -100.00 9.53 -25,382
2016-09-20 2016-09-17 4 M?????? ACUCELA INC.
Restricted Stock Unit
M - Exercise -2,663 93,222 -2.78
2016-09-20 2016-09-17 4 M?????? ACUCELA INC.
Common Stock
M - Exercise 2,663 2,663
2016-08-18 2016-08-18 4 M?????? ACUCELA INC.
Common Stock
S - Sale -31,962 0 -100.00 10.81 -345,509
2016-08-18 2016-08-17 4 M?????? ACUCELA INC.
Restricted Stock Unit
M - Exercise -31,962 95,885 -25.00
2016-08-18 2016-08-17 4 M?????? ACUCELA INC.
Common Stock
M - Exercise 31,962 31,962
2016-07-14 2016-07-12 4 M?????? ACUCELA INC.
Non-Qualified Stock Option (right to buy)
A - Award 87,555 87,555
2016-07-14 2016-07-12 4 M?????? ACUCELA INC.
Incentive Stock Option (right to buy)
A - Award 32,445 32,445
2015-08-19 2015-08-17 4 M?????? ACUCELA INC.
Restricted Stock Unit
A - Award 127,847 127,847
2015-08-19 3 M?????? ACUCELA INC.
Common Stock
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)